Survivors (n = 22), n (%) | Non-survivors (n = 14), n (%) | p | Adjustedpa | |
---|---|---|---|---|
Age (years, median, IQR) | 76.5, 69.3–84.3 | 71, 60.3–79 | 0.175 | |
Male sex | 17 (77.3) | 10 (71.4) | 0.988 | |
Underlying disease | ||||
Immunosuppressionb | 5 (22.7) | 4 (28.6) | 0.988 | |
Diabetes mellitus | 9 (40.9) | 9 (64.3) | 0.305 | |
Chronic obstructive lung disease | 2 (9.1) | 3 (21.4) | 0.574 | |
Hemodialysis | 5 (22.7) | 6 (42.9) | 0.364 | |
Malignancy | 7 (31.8) | 7 (50) | 0.458 | |
Liver cirrhosis | 2 ( 9.1) | 1 (7.1) | 1.000 | |
Cerebral vascular disease | 6 (27.3) | 4 (28.6) | 1.000 | |
Charlson comorbidity score (median, IQR) | 3, 2–5 | 4, 3–8.3 | 0.171 | |
Pitt bacteremia score (mean ± SD) | 3.3 ± 3.1 | 5.9 ± 3.7 | 0.037 | 0.847 |
APACHE II score (mean ± SD) | 20.1 ± 0.6 | 27.6 ± 11.0 | 0.016 | 0.958 |
Acquired after ICU >48 h | 3 (13.6) | 11 (78.6) | <0.001 | 0.021 |
Infection sources and clinical syndrome | ||||
Pneumonia | 3 (13.6) | 7 (50) | 0.047 | 0.569 |
Intra-abdominal infection other than biliary-tract infection | 2 (9.1) | 3 (21.4) | 0.574 | |
Biliary-tract infection | 7 (31.8) | 0 (0) | ||
Unknown primary focus | 8 (36.4) | 2 (14.3) | 0.289 | |
Presentation with septic shock | 9 (40.9) | 10 (71.4) | 0.147 | |
Appropriate antibiotic treatment | 12 (54.6) | 6 (42.9) | 0.733 | |
Ertapenem non-susceptibility | 6 (27.3) | 2 (14.3) | 0.628 | |
Tigecycline MIC >4 μg/mL | 10 (45.5) | 8 (57.1) | 0.733 | |
Tigecycline MIC >6 μg/mL | 4 (18.2) | 6 (42.9) | 0.220 | |
ESBL-producing strain | 10 (45.5) | 8 (57.1) | 0.733 |